This company has been acquired
Myovant Sciences Future Growth
Future criteria checks 5/6
Key information
59.0%
Earnings growth rate
60.27%
EPS growth rate
| Biotechs earnings growth | 23.7% |
| Revenue growth rate | 27.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 10 Mar 2023 |
Recent future growth updates
Recent updates
Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M
Jan 26Not The Buyout Offer That Myovant Shareholders Hoped For
Oct 25Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer
Oct 03Women Can Thank Pfizer And Myovant For MYFEMBREE
Sep 20Myovant Sciences: Regulatory Overhang Cleared
Aug 29Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication
Aug 09Myovant stock gains ~6% after hours on Q1 revenue jump
Jul 27Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree
Jul 18Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Apr 28
Myovant: Poised To Overcome Regulatory Issues
Apr 26Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels
Apr 13Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play
Mar 26Myovant: Catalysts Powering More Upside
Jan 02Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates
May 14New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)
Feb 17Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates
Feb 13Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Jan 12Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?
Dec 23
Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain
Nov 18Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2025 | 618 | -74 | N/A | N/A | 2 |
| 3/31/2024 | 555 | -76 | N/A | N/A | 3 |
| 3/31/2023 | 418 | -153 | N/A | N/A | 2 |
| 12/31/2022 | 379 | -184 | -271 | -270 | N/A |
| 9/30/2022 | 333 | -190 | -260 | -259 | N/A |
| 6/30/2022 | 306 | -166 | -232 | -231 | N/A |
| 3/31/2022 | 231 | -206 | -270 | -269 | N/A |
| 12/31/2021 | 198 | -228 | -263 | -261 | N/A |
| 9/30/2021 | 145 | -238 | 403 | 405 | N/A |
| 6/30/2021 | 67 | -284 | 318 | 319 | N/A |
| 3/31/2021 | 59 | -255 | 369 | 371 | N/A |
| 12/31/2020 | 35 | -239 | 443 | 444 | N/A |
| 9/30/2020 | 33 | -250 | -198 | -197 | N/A |
| 6/30/2020 | 33 | -254 | -217 | -216 | N/A |
| 3/31/2020 | N/A | -289 | -222 | -221 | N/A |
| 12/31/2019 | N/A | -299 | -256 | -255 | N/A |
| 9/30/2019 | N/A | -284 | -252 | -250 | N/A |
| 6/30/2019 | N/A | -279 | -247 | -246 | N/A |
| 3/31/2019 | N/A | -274 | -225 | -224 | N/A |
| 12/31/2018 | N/A | -247 | -207 | -206 | N/A |
| 9/30/2018 | N/A | -218 | -176 | -175 | N/A |
| 6/30/2018 | N/A | -182 | -136 | -135 | N/A |
| 3/31/2018 | N/A | -143 | -118 | -117 | N/A |
| 12/31/2017 | N/A | -117 | -94 | -93 | N/A |
| 9/30/2017 | N/A | -83 | -70 | -69 | N/A |
| 6/30/2017 | N/A | -88 | -46 | -45 | N/A |
| 3/31/2017 | N/A | -83 | -19 | -18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MYOV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).
Earnings vs Market: MYOV is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MYOV is expected to become profitable in the next 3 years.
Revenue vs Market: MYOV's revenue (27.6% per year) is forecast to grow faster than the US market (6.9% per year).
High Growth Revenue: MYOV's revenue (27.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MYOV's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/12 11:36 |
| End of Day Share Price | 2023/03/09 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Myovant Sciences Ltd. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Mohit Bansal | Citigroup Inc |
| Jason Butler | Citizens JMP Securities, LLC |